Table 1. Clinicopathological variables of the patient cohort (n = 501).
| Variable | Number of patients | |
|---|---|---|
| Age | ||
| <60 years | 169 (34%) | |
| 60–65 years | 187 (37%) | |
| >65 years | 143 (29%) | |
| PSA group (μg/L) | ||
| <10 | 306 (61%) | |
| 10–20 | 116 (23%) | |
| >20 | 38 (8%) | |
| pT-category a | ||
| pT2 | 209 (42%) | |
| pT3a | 160 (32%) | |
| pT3b | 52 (10%) | |
| Gleason group | ||
| <7 | 181 (36%) | |
| 7 | 199 (40%) | |
| >7 | 96 (19%) | |
| Extraprostatic extension | ||
| Yes | 203 (41%) | |
| Surgical margin | ||
| Positive | 190 (38%) | |
| Lymph node status | ||
| N+ | 21 (4%) | |
| BCR | ||
| Yes | 157 (31%) | |
| Alive | 444 (89%) | |
| Death due Pca | 20 (4%) | |
| Death, other | 37 (7%) | |
| Follow-up time (months) | ||
| Median | 91 | |
| Range | 1–167 |
a Pathological T (pT) category refers to the stage of primary tumor in the TNM tumor staging system. pT2 = Tumor confined within prostate, pT3a = Extracapsular extension, pT3b = tumor invading seminal vesicle(s).